• Explore /
  • Poster
  • / IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

Abstract Poster

Authors

null

Robert J. Motzer

Memorial Sloan Kettering Cancer Center, New York, NY

Robert J. Motzer , Thomas Powles , Michael B. Atkins , Bernard Escudier , David F. McDermott , Cristina Suarez , Sergio Bracarda , Walter Michael Stadler , Frede Donskov , Jae-Lyun Lee , Robert E. Hawkins , Alain Ravaud , Boris Y. Alekseev , Michael D. Staehler , Motohide Uemura , Francis Donaldson , Shi Li , Mahrukh A. Huseni , Christina Schiff , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02420821

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 578)

DOI

10.1200/JCO.2018.36.6_suppl.578

Abstract #

578

Poster Bd #

E15

Abstract Disclosures

Similar Posters

First Author: Brian I. Rini

First Author: David F. McDermott

First Author: Vassiliki Papadimitrakopoulou

First Author: Yuming Zhu